Insufficient ex vivo expansion of Vα24⁺ natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14⁺ cells

References

• Bendelac A, Rivera MN, Park SH, et al. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535–62
   PubMed Web of Science ®Google Scholar
• Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521–8
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379–88
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191: 661–8
   PubMed Web of Science ®Google Scholar
• Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998; 188: 1529–34
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626–9
   PubMed Web of Science ®Google Scholar
• Exley M, Garcia J, Balk SP, et al. Requirements for CD1d recognition by human invariant Valpha24+ CD4− CD8− T cells. J Exp Med 1997; 186: 109–20
   PubMed Web of Science ®Google Scholar
• Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22: 817–90
   PubMed Web of Science ®Google Scholar
• Maeda M, Shadeo A, MacFadyen AM, et al. CD1d-independent NKT cells in beta 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells. J Immunol 2004; 172: 6115–22
   PubMed Web of Science ®Google Scholar
• Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol Res 2004; 30: 139–53
   PubMed Web of Science ®Google Scholar
• Toura I, Kawano T, Akutsu Y, et al. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999; 163: 2387–91
   PubMed Web of Science ®Google Scholar
• Kawano T, Nakayama T, Kamada N, et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999; 59: 5102–5
   PubMed Web of Science ®Google Scholar
• Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103: 383–9
   PubMed Web of Science ®Google Scholar
• Nieda M, Nicol A, Koezuka Y, et al. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol 1999; 60: 10–19
   PubMed Web of Science ®Google Scholar
• Takahashi T, Nieda M, Koezuka Y, et al. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164: 4458–64
   PubMed Web of Science ®Google Scholar
• Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167: 4046–50
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Seino K, Ishikawa Y, et al. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 2002; 168: 6494–9
   PubMed Web of Science ®Google Scholar
• Asada-Mikami R, Heike Y, Harada Y, et al. Increased expansion of V alpha 24+ T cells derived from G-CSF-mobilized peripheral blood stem cells as compared to peripheral blood mononuclear cells following alpha-galactosylceramide stimulation. Cancer Sci 2003; 94: 383–8
   PubMed Web of Science ®Google Scholar
• Harada Y, Imataki O, Heike Y, et al. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials. J Immunother 2005; 28: 314–21
   PubMed Web of Science ®Google Scholar
• Imataki O, Heike Y, Ishida T, et al. Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells. J Immunother 2006; 29: 320–7
   PubMed Web of Science ®Google Scholar
• Crough T, Purdie DM, Okai M, et al. Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 2004; 91: 1880–6
   Google Scholar
• Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992; 52: 1386–92
   PubMed Web of Science ®Google Scholar
• Xu H, Chun T, Colmone A, et al. Expression of CD1d under the control of a MHC class Ia promoter skews the development of NKT cells, but not CD8+ T cells. J Immunol 2003; 171: 4105–12
   PubMed Web of Science ®Google Scholar
• Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077–82
   PubMed Web of Science ®Google Scholar
• Chouaib S, Asselin-Paturel C, Mami-Chouaib F, et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493–7
   PubMedGoogle Scholar
• Goto S, Sato M, Kaneko R, et al. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 1999; 48: 435–42
   PubMed Web of Science ®Google Scholar
• Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999; 48: 353–62
   PubMed Web of Science ®Google Scholar
• van der Vliet HJ, Molling JW, Nishi N, et al. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 2003; 63: 4101–6
   PubMed Web of Science ®Google Scholar
• Uldrich AP, Crowe NY, Kyparissoudis K, et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 2005; 175: 3092–101
   PubMed Web of Science ®Google Scholar